Loudon Investment Management LLC Lowers Stock Position in Amgen Inc. $AMGN

Loudon Investment Management LLC cut its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 28.3% in the 3rd quarter, HoldingsChannel reports. The firm owned 5,472 shares of the medical research company’s stock after selling 2,157 shares during the period. Loudon Investment Management LLC’s holdings in Amgen were worth $1,544,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Evelyn Partners Investment Management LLP purchased a new stake in Amgen during the second quarter valued at about $32,000. Howard Hughes Medical Institute purchased a new position in shares of Amgen in the 2nd quarter worth about $32,000. Cloud Capital Management LLC purchased a new position in shares of Amgen in the 3rd quarter worth about $34,000. AXS Investments LLC bought a new position in shares of Amgen during the 3rd quarter valued at about $42,000. Finally, Winnow Wealth LLC purchased a new position in shares of Amgen during the 3rd quarter valued at about $47,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the company. Guggenheim boosted their target price on Amgen from $305.00 to $347.00 and gave the stock a “neutral” rating in a research report on Friday, February 6th. HSBC reiterated a “buy” rating and set a $425.00 price target on shares of Amgen in a research report on Wednesday, December 10th. The Goldman Sachs Group lifted their price target on shares of Amgen from $403.00 to $415.00 and gave the stock a “buy” rating in a research note on Wednesday, February 4th. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Amgen from $285.00 to $295.00 and gave the stock a “hold” rating in a report on Thursday, February 5th. Finally, Sanford C. Bernstein cut shares of Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 price objective for the company. in a research note on Tuesday, January 20th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $354.00.

Amgen Trading Up 0.0%

Shares of AMGN stock opened at $366.25 on Tuesday. The business has a 50-day moving average of $358.64 and a 200 day moving average of $326.25. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $391.29. The stock has a market capitalization of $197.43 billion, a PE ratio of 25.74, a P/E/G ratio of 3.63 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The business had revenue of $9.87 billion for the quarter, compared to analysts’ expectations of $9.46 billion. During the same period in the previous year, the firm earned $5.31 EPS. The business’s quarterly revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, sell-side analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be paid a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s payout ratio is presently 70.84%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.